Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US5288721047
Biotechnology & Medical Research
| Market Cap | 1.06B 931M 860M 791M 1.49B 102B 1.52B 10.28B 4.03B 50.09B 3.99B 3.9B 173B | P/E 2026 * |
-15.2x | P/E 2027 * | -12.6x |
|---|---|---|---|---|---|
| Enterprise Value | 1.06B 931M 860M 791M 1.49B 102B 1.52B 10.28B 4.03B 50.09B 3.99B 3.9B 173B | EV / Sales 2026 * |
27.8x | EV / Sales 2027 * | 52.7x |
| Free-Float |
98.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Lexicon Pharmaceuticals, Inc.
| 1 day | +7.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Exton
CEO | Chief Executive Officer | 56 | 08/07/2024 |
Scott Coiante
DFI | Director of Finance/CFO | 59 | 02/01/2025 |
Michael Davies
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Samuel Barker
CHM | Chairman | 83 | 01/01/2005 |
Ray Debbane
CHM | Chairman | 71 | 27/02/2012 |
| Director/Board Member | 67 | 28/08/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.56% | +0.99% | - | - | 1.06B | |
| +0.21% | -1.34% | +53.17% | +60.65% | 53.83B | |
| +5.37% | +0.75% | +50.39% | +83.03% | 52.1B | |
| -0.67% | -0.62% | +5.53% | +409.46% | 23.48B | |
| +11.37% | +2.20% | -15.48% | -14.55% | 23.13B | |
| +3.46% | +0.79% | +34.01% | -4.47% | 19.36B | |
| -1.18% | -1.15% | +30.12% | -32.02% | 17.56B | |
| -1.67% | -8.56% | +163.95% | +284.69% | 15.2B | |
| +3.62% | -2.42% | +29.70% | +663.64% | 14.83B | |
| -2.66% | +0.36% | +27.07% | +183.04% | 14.06B | |
| Average | +1.89% | -0.34% | +42.05% | +181.50% | 25.95B | |
| Weighted average by Cap. | +1.73% | -0.73% | +41.79% | +141.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.17M 33.45M 30.92M 28.44M 53.66M 3.68B 54.52M 370M 145M 1.8B 143M 140M 6.2B | 20.15M 17.66M 16.33M 15.02M 28.33M 1.94B 28.79M 195M 76.53M 951M 75.68M 74.02M 3.28B |
| Net income | -66.94M -58.67M -54.23M -49.88M -94.11M -6.45B -95.62M -648M -254M -3.16B -251M -246M -10.88B | -88.26M -77.36M -71.51M -65.77M -124M -8.51B -126M -855M -335M -4.16B -331M -324M -14.35B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
